trial_id	trialacronym	phase	recruitmentstatus	approvaldate	actualstartdate	short_title	drug_list	drug_classes	secondaryid	studytitle	healthcondition	hospital	ext_weblink
NCT03454451	CPI-006-001	Phase 1	Recruiting	06/03/2018	25/04/2018	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; Ciforadenant; Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody	CPI-006-001	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	Non-Small Cell Lung Cancer; Renal Cell Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Cervical Cancer; Ovarian Cancer; Pancreatic Cancer; Endometrial Cancer; Sarcoma; Squamous Cell Carcinoma of the Head and Neck; Bladder Cancer; Metastatic Castration Resistant Prostate Cancer; Non-hodgkin Lymphoma	Chris O'Brien Lifehouse - Camperdown; St. Vincent's Hospital - Darlinghurst; Westmead Hospital - Westmead; Royal Brisbane and Women's Hospital - Herston; Monash Health - Clayton	https://clinicaltrials.gov/ct2/show/NCT03454451
NCT03629756	AB928CSP0005	Phase 1	Recruiting	14/08/2018	24/07/2018	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies	AB122; AB122 + AB928; AB928	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-1_monoclonal_antibody	AB928CSP0005	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies	Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Breast Cancer; Colorectal Cancer; Melanoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Merkel Cell Carcinoma; GastroEsophageal Cancer; Renal Cell Carcinoma; Castration-resistant Prostate Cancer	Kogarah, Australia - Kogarah; Greenslopes, Australia - Greenslopes; Malvern, Australia - Malvern	https://clinicaltrials.gov/ct2/show/NCT03629756
NCT03530397	D7980C00001	Phase 1	Recruiting	21/05/2018	24/04/2018	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.	Carboplatin; Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed; MEDI5752; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; bispecific_PD-L1/CTLA-4_antibody; platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	D7980C00001	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.	Selected Advanced Solid Tumors; NSCLC; Lung Cancer; RCC; Renal Cell Carcinoma; Kidney Cancer	Research Site - Heidelberg; Research Site - Melbourne; Research Site - Randwick	https://clinicaltrials.gov/ct2/show/NCT03530397
NCT02609776	CR108064	Phase 1	Recruiting	20/11/2015	24/05/2016	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Amivantamab; Amivantamab + Lazertinib; Lazertinib	EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation; bispecific_c-Met_EGFR_monoclonal_antibody	61186372EDI1001; CR108064	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Non-Small-Cell Lung Cancer	Chris O'Brien Lifehouse - Camperdown; Austin Hospital - Heidelberg; St George Hospital - Kogarah; Princess Alexandra Hospital - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02609776
NCT03473925	MK-7123-034	Phase 2	Active, not recruiting	22/03/2018	10/04/2018	A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors	Navarixin; Navarixin + Pembrolizumab; Pembrolizumab	CXCR2_antagonist + anti-PD-1_monoclonal_antibody; CXCR2_antagonist; anti-PD-1_monoclonal_antibody	MK-7123-034; 7123-034	A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors	Solid Tumors; Non-small Cell Lung Cancer; Castration Resistant Prostate Cancer; Microsatellite Stable Colorectal Cancer	Blacktown Hospital Western Sydney Local Health District ( Site 0024) - Blacktown; Scientia Clinical Research ( Site 0021) - Randwick; Peter MacCallum Cancer Centre ( Site 0023) - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03473925
ACTRN12616001597482	APG-1252-AU-001	Phase 1	Recruiting	18/11/2016	16/04/2018	A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or other solid tumors	APG-1252	BCL2_inhibitor	None	A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or other solid tumors	Solid tumour; Small cell lung cancer		https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371737
NCT02857270	I8S-MC-JUAB	Phase 1	Recruiting	05/08/2016	29/09/2016	A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer	Abemaciclib; Abemaciclib + LY3214996; Cetuximab; Cetuximab + Encorafenib + LY3214996; Encorafenib; Gemcitabine; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam; Midazolam; Nab-paclitaxel	benzodiazepam; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor; antimetabolite; ERK_inhibitor + benzodiazepam; ERK_inhibitor; CDK4/6_inhibitor; ERK_inhibitor + antimetabolite + taxane; CDK4/6_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; taxane	I8S-MC-JUAB; 16419	A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer	Advanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Colorectal Cancer	St Vincent's Hospital - Sydney; Linear Clinical Research Ltd - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02857270
NCT02628535	CP-MGD009-01	Phase 1	Terminated	11/12/2015	01/09/2015	Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms	MGD009	humanized_B7-H3_x_CD3_dual-affinity_re-targeting_protein	CP-MGD009-01	Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms	Mesothelioma; Bladder Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non Small Cell Lung Cancer; Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Thyroid Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer; Colon Cancer; Soft Tissue Sarcoma	Chris O'Brien Lifehouse - Camperdown; Saint Vincent's Hospital Sydney - Darlinghurst; Princess Alexandra Hospital - Woolloongabba; Austin Health - Heidelberg; Linear Clinical Research - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02628535
NCT02658890	CA017-003	Phase 1/Phase 2	Recruiting	20/01/2016	18/02/2016	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Ipilimumab; Ipilimumab + Linrodostat + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab	IDO1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2015-004914-79; CA017-003	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer	The Kinghorn Cancer Centre - Darlinghurst; Melanoma Institute Australia - North Sydney; Local Institution - Westmead; Princess Alexandra Hospital - Brisbane; Local Institution - Clayton; The Royal Melbourne Hospital - Melbourne; Linear Clinical Research Ltd - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02658890
NCT03317496	B9991023	Phase 2	Recruiting	23/10/2017	21/12/2017	A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES	Avelumab; Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody	B9991023; B9991023	A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES	Non-small Cell Lung Cancer; Urothelial Cancer	Chris O'Brien Lifehouse - Camperdown; St Vincent's Public Hospital Sydney - Darlinghurst; Sunshine Coast University Hospital - Birtinya; Slade Health Pharmacy - Geebung; Cancer Melbourne - Richmond; Epworth Healthcare - Epworth Richmond - Richmond; Western Health, Sunshine Hospital - St Albans	https://clinicaltrials.gov/ct2/show/NCT03317496
NCT03319940	NCT03319940	Phase 1	Recruiting	24/10/2017	26/12/2017	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	AMG 757; AMG 757 + Pembrolizumab; Pembrolizumab	bispecific_T_cell_engager_targeting_DLL3; anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_DLL3; anti-PD-1_monoclonal_antibody	20160323	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	Small Cell Lung Carcinoma	Research Site - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03212404	CK-301-101	Phase 1	Recruiting	11/07/2017	20/09/2017	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Cosibelimab	anti-PD-L1_monoclonal_antibody	CK-301-101	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Malignant Mesothelioma, Advanced; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Classical Hodgkin Lymphoma; Colorectal Cancer; Cutaneous Squamous Cell Carcinoma; Non Hodgkin Lymphoma; Endometrial Cancer	Research Site - Wollongong; Research Site - Box Hill; Research Site - Malvern	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03708328	NP40435	Phase 1	Recruiting	17/10/2018	15/10/2018	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Cisplatin; Cisplatin + RO7121661; RO7121661	platinum-based_antineoplastic_agent; bispecific_PD-1/TIM-3_antibody + platinum-based_antineoplastic_agent; bispecific_PD-1/TIM-3_antibody	2018-000982-35; NP40435	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Solid Tumors; Metastatic Melanoma; Non-small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)		https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03811652	D8540C00002	Phase 1	Recruiting	21/01/2019	20/12/2018	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Abiraterone; Abiraterone + Enzalutamide; Capecitabine; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin; Cisplatin; Enzalutamide; Fluorouracil; Irinotecan; MEDI7247; Oxaliplatin	antimetabolite; topoisomerase_inhibitor; antimetabolite + antimetabolite + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation; anti-ASCT2_antibody-drug_conjugate; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	D8540C00002	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Metastatic Castration-resistant Prostate Cancer (mCRPC)	Research Site - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03157128	LIBRETTO-001	Phase 1/Phase 2	Recruiting	17/05/2017	09/05/2017	A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Selpercatinib	RET_inhibitor	2017-000800-59; LOXO-RET-17001	A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor	Peter MacCallum Cancer Institute - Melbourne; Royal North Shore Hospital - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03631784	KEYNOTE-799	Phase 2	Recruiting	15/08/2018	19/10/2018	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + radiotherapy; Cisplatin; Cisplatin + Pembrolizumab + Pemetrexed + radiotherapy; Paclitaxel; Pembrolizumab; Pemetrexed; Thoracic Radiation Therapy; radiotherapy	taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody; radiotherapy; platinum-based_antineoplastic_agent; antimetabolite	MK-3475-799; 3475-799	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).	Non-small Cell Lung Cancer	Blacktown Hospital Western Sydney Local Health District ( Site 0204) - Blacktown; MNCCI Port Macquarie Base Hospital ( Site 0200) - Port Macquarie; Southern Medical Day Care Centre ( Site 0201) - Wollongong; Ballarat Health Services ( Site 0206) - Ballarat	https://clinicaltrials.gov/ct2/show/NCT03631784
NCT02568267	STARTRK-2	Phase 2	Recruiting	05/10/2015	19/11/2015	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Crizotinib; Entrectinib	TRK_inhibitor,first_generation; MET_inhibitor,type_1; ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation	2015-003385-84; RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor	Border Medical Oncology Research Unit - Albury; Liverpool Hospital - Liverpool; Newcastle Private Hospital - New Lambton Heights; Flinders Medical Centre - Bedford Park; Austin Hospital - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02568267
NCT03549000	CNZV930X2101	Phase 1	Recruiting	07/06/2018	18/07/2018	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	NIR178; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody	2018-000153-51; CNZV930X2101	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	Non-small Cell Lung Cancer (NSCLC); Triple Negative Breast Cancer (TNBC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer Microsatellite Stable (MSS); Ovarian Cancer; Renal Cell Carcinoma (RCC); Metastatic Castration Resistant Prostate Cancer (mCRPC)	Novartis Investigative Site - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03549000
NCT04000529	CTNO155B12101	Phase 1	Recruiting	27/06/2019	30/07/2019	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Ribociclib; Ribociclib + TNO155; Spartalizumab; Spartalizumab + TNO155; TNO155	SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + SHP2_inhibitor; anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor	CTNO155B12101	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Non-small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Esophageal SCC; Gastrointestinal Stromal Tumors; Colorectal Cancer	Novartis Investigative Site - Westmead	https://clinicaltrials.gov/ct2/show/NCT04000529
NCT03829332	LEAP-007	Phase 3	Recruiting	04/02/2019	13/03/2019	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	MK-7902-007; 7902-007	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)	Non-small Cell Lung Cancer	Orange Health Services ( Site 0002) - Orange; Wollongong Private Hospital ( Site 0005) - Wollongong; The Prince Charles Hospital ( Site 0011) - Chermside; Ballarat Oncology and Haematology Services ( Site 0008) - Wendouree; St John of God Murdoch Medical Clinic ( Site 0001) - Perth	https://clinicaltrials.gov/ct2/show/NCT03829332
NCT03976375	LEAP-008	Phase 3	Recruiting	06/06/2019	26/06/2019	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Cisplatin; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor; taxane; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	MK-7902-008; 7902-008	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Metastatic Non-Small Cell Lung Cancer	Blacktown Hospital ( Site 0004) - Blacktown; Port Macquarie Base Hospital ( Site 0003) - Port Macquarie; Westmead Hospital ( Site 0005) - Westmead; Southern Medical Day Care Centre ( Site 0001) - Wollongong; Princess Alexandra Hospital - Division of Cancer Services ( Site 0002) - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03976375
NCT02775435	KEYNOTE-407	Phase 3	Recruiting	15/05/2016	09/06/2016	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Placebo	taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane + taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; glucocorticoid; platinum-based_antineoplastic_agent + taxane + taxane; placebo	2016-000229-38; 3475-407	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	Merck Sharp &amp; Dohme - North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT04165031	J2K-MC-JZKA	Phase 1/Phase 2	Recruiting	15/11/2019	28/11/2019	A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation	Abemaciclib; Abemaciclib + LY3499446; Cetuximab; Cetuximab + LY3499446; Docetaxel; Erlotinib; Erlotinib + LY3499446; LY3499446	CDK4/6_inhibitor + KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor; KRAS_G12C_inhibitor; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; EGFR_inhibitor,first_generation; taxane; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	J2K-MC-JZKA; 17501	A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation	Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer	St Vincent's Hospital - Darlinghurst; Linear Clinical Research Ltd - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04165031
NCT03516981	KEYNOTE-495	Phase 2	Recruiting	07/05/2018	01/10/2018	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Lenvatinib; Lenvatinib + Pembrolizumab; MK-1308; MK-1308 + Pembrolizumab; MK-4280; MK-4280 + Pembrolizumab; Pembrolizumab	VEGF_inhibitor; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-3475-495; 3475-495	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Advanced Non-Small Cell Lung Cancer	Blacktown Hospital Western Sydney Local Health District ( Site 0200) - Blacktown; Greenslopes Private Hospital ( Site 0202) - Greenslopes; Fiona Stanley Hospital ( Site 0201) - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03516981
NCT03515837	KEYNOTE-789	Phase 3	Recruiting	04/05/2018	29/06/2018	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Dexamethasone; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; glucocorticoid; antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; antimetabolite	MK-3475-789; 3475-789	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Non-small Cell Lung Cancer	Chris OBrien Lifehouse ( Site 0200) - Camperdown; Eastern Health ( Site 0202) - Box Hill; Austin Health ( Site 0203) - Heidelberg; Westmead Hospital ( Site 0201) - Westmead	https://clinicaltrials.gov/ct2/show/NCT03515837
NCT02974725	CLXH254X2102	Phase 1	Recruiting	28/11/2016	24/02/2017	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	LTT462; LTT462 + LXH254; LXH254; LXH254 + Ribociclib; LXH254 + Trametinib; Ribociclib; Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor; ERK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor; RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor	2016-004293-18; CLXH254X2102	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	Non-Small Cell Lung Cancer; Melanoma	Novartis Investigative Site - Melbourne; Novartis Investigative Site - Prahran	https://clinicaltrials.gov/ct2/show/NCT02974725
NCT04256421	SKYSCRAPER-02	Phase 3	Recruiting	05/02/2020		A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Carboplatin; Etoposide; Placebo; Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; topoisomerase_inhibitor; platinum-based_antineoplastic_agent	2019-003301-97; GO41767	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Chris O'Brien Lifehouse - Camperdown; Nepean Hospital; Nepean Cancer Care Centre - Kingswood; Sunshine Coast University Hospital; The Adem Crosby Centre - Birtinya; Lyell McEwin Hospital; Oncology Clinical Trials, Chemotherapy Day Unit - Elizabeth Vale; Peter Maccallum Cancer Centre - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04256421
NCT04294810	SKYSCRAPER-01	Phase 3	Recruiting	04/03/2020	04/03/2020	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	placebo; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	2019-002925-31; GO41717	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	St Vincent's Hospital Sydney - Darlinghurst; Princess Alexandra Hospital - Woolloongabba; Frankston Hospital; Oncology/Haematology - Frankston; Austin Hospital Olivia Newton John Cancer Centre - Heidelberg; Peter Maccallum Cancer Centre - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04294810
NCT03829319	LEAP-006	Phase 3	Recruiting	04/02/2019	25/03/2019	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Carboplatin; Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Cisplatin; Lenvatinib; Pembrolizumab; Pemetrexed; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; VEGF_inhibitor; placebo; antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	2018-003824-35; 7902-006	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Nonsquamous Non-small Cell Lung Cancer	Blacktown Hospital Western Sydney Local Health District ( Site 0008) - Blacktown; Port Macquarie Base Hospital ( Site 0001) - Port Macquarie; Chris OBrien Lifehouse ( Site 0006) - Sydney; Westmead Hospital ( Site 0009) - Sydney; Cairns Hospital ( Site 0002) - Cairns; The Prince Charles Hospital ( Site 0010) - Chermside; Ballarat Health Services ( Site 0003) - Ballarat	https://clinicaltrials.gov/ct2/show/NCT03829319
NCT03430063	R2810-ONC-1763	Phase 2	Recruiting	09/02/2018	29/05/2018	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2017-003684-35; R2810-ONC-1763	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	Regeneron Research Site - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03088540	R2810-ONC-1624	Phase 3	Recruiting	23/03/2017	29/05/2017	A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer	Carboplatin; Cemiplimab; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; taxane	2016-004407-31; R2810-ONC-1624	A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer	Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer	Clinical Study Site - Albury; Clinical Study Site - Wollongong; Clinical Study Site - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT03088540
NCT03052608	B7461006	Phase 3	Recruiting	14/02/2017	14/04/2017	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER	Crizotinib; Lorlatinib	ALK_inhibitor,first_generation; ROS1_inhibitor; MET_inhibitor,type_1; ALK_inhibitor,third_generation	2016-003315-35; B7461006	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER	Carcinoma, Non-Small-Cell Lung	Peter MacCallum Cancer Centre - Melbourne; Royal Melbourne Hospital - Parkville	https://clinicaltrials.gov/ct2/show/NCT03052608
NCT03358875	BGB-A317-303	Phase 3	Recruiting	02/12/2017	30/11/2017	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Cisplatin; Docetaxel; Tislelizumab	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; taxane	2018-000245-39; BGB-A317-303	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03178552	B-FAST	Phase 2/Phase 3	Recruiting	07/06/2017	22/09/2017	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Alectinib; Atezolizumab; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cobimetinib; Entrectinib; Gemcitabine; Pemetrexed; Vemurafenib	BRAF_V600_inhibitor; antimetabolite; ROS1_inhibitor; platinum-based_antineoplastic_agent; ALK_inhibitor,second_generation; antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor; anti-PD-L1_monoclonal_antibody; TRK_inhibitor,first_generation	2017-000076-28; BO29554	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	Royal North Shore Hospital; Department of Medical Oncology - St Leonards; The Prince Charles Hospital; Oncology Dept. - Chermside; Ashford Cancer Center Research - Kurralta Park; Austin Hospital; Medical Oncology - Heidelberg; Sir Charles Gairdner Hospital - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT02504489	DUBLIN-3	Phase 3	Recruiting	22/07/2015	01/12/2015	Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion	Dexamethasone; Dexamethasone + Docetaxel; Docetaxel; Docetaxel + Plinabulin; Placebo; Plinabulin	glucocorticoid + taxane; taxane + tubulin_polymerization_inhibitor; glucocorticoid; placebo; taxane; tubulin_polymerization_inhibitor	BPI-2358-103	Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion	Non-Small Cell Lung Cancer	Blacktown Cancer Centre - Blacktown; Border Medical Oncology Research Unit - East Albury; Gosford Hospital - Gosford; Adult Mater Hospital - South Brisbane; Peninsula and South East Oncology - Melbourne; Epworth Hospital - Richmond; Fiona Stanley Hospital - Murdoch; Perth Oncology/Mount Hospital - Perth; St John of God Hospital, Subiaco - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02504489
NCT03994393	ILLUMINATE	Phase 2	Recruiting	21/06/2019	23/10/2018	A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	Durvalumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	ALTG 16/009; CTC 0209	A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	EGFR Mutant Advanced Non Small Cell Lung Cancer	Bankstown Hospital - Bankstown; Gosford Hospital - Gosford; St George Hospital - Kogarah; Liverpool Hospital - Liverpool; The Prince Charles Hospital - Chermside; Princess Alexandra Hospital - Woolloongabba; Flinders Medical Centre - Bedford Park; Royal Hobart Hospital - Hobart; Monash Medical Centre - Clayton - Clayton; Peter MacCallum Cancer Centre - Melbourne; St Vincent's Hospital (Melbourne) - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03994393
NCT03631199	CANOPY-1	Phase 3	Recruiting	15/08/2018	21/12/2018	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)	Carboplatin; Cisplatin; Cisplatin + Pembrolizumab + canakinumab; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo; canakinumab	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; placebo; antimetabolite; taxane; anti-IL-1beta_antibody; anti-IL-1beta_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	2018-001547-32; CACZ885U2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)	Non-small Cell Lung Cancer	Novartis Investigative Site - Westmead; Novartis Investigative Site - Wooloongabba; Novartis Investigative Site - Clayton; Novartis Investigative Site - Melbourne; Novartis Investigative Site - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03631199
NCT03207867	CNIR178X2201	Phase 2	Recruiting	05/07/2017	26/04/2016	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	NIR178; NIR178 + Spartalizumab; Spartalizumab	adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	2017-000241-49; CNIR178X2201	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	NSCLC, Non Small Cell Lung Cancer; RCC, Renal Cell Cancer; Pancreatic Cancer; Urothelial Cancer; Head and Neck Cancer; DLBCL, Diffused Large B Cell Lymphoma; MSS, Microsatellite Stable Colon Cancer; TNBC, Triple Negative Breast Cancer; Melanoma	Novartis Investigative Site - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03207867
NCT03337698	Morpheus-Lung	Phase 1/Phase 2	Recruiting	09/11/2017	02/01/2018	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Bevacizumab; Carboplatin; Cibisatamab; Ciforadenant; Cobimetinib; Docetaxel; Docetaxel + Idasanutlin; Gemcitabine; Idasanutlin; Ipatasertib; Linagliptin; Pemetrexed; Tocilizumab	dipeptidyl_peptidase-4_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-IL-6_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; MDM2_inhibitor; anti-CEA/CD3_bispecific_antibody + anti-PD-L1_monoclonal_antibody; anti-CEA/CD3_bispecific_antibody; taxane; MDM2_inhibitor + taxane; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; MEK_inhibitor	2017-001267-21; BO39610	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Carcinoma, Non-Small-Cell Lung	Peter Mac Callum Cancer Center - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03337698
NCT03735121	BP40657	Phase 1/Phase 2	Recruiting	08/11/2018	27/12/2018	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Bevacizumab; Carboplatin; Paclitaxel; rHuPH20	platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; taxane; anti-PD-L1_monoclonal_antibody	BP40657	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT03735121
NCT04139317	CINC280I12201	Phase 2	Recruiting	25/10/2019	22/01/2020	A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1= 50%	Capmatinib; Capmatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	CINC280I12201	A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1= 50%	Non-small Cell Lung Cancer (NSCLC)	Novartis Investigative Site - Shepparton	https://clinicaltrials.gov/ct2/show/NCT04139317
NCT03625323	TACTI-002	Phase 2	Recruiting	10/08/2018	18/02/2019	TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote-PN798; TACTI-002	TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)	NSCLC; HNSCC	Tasman Health Care - Southport; St John of God Subiaco Hospital - Perth	https://clinicaltrials.gov/ct2/show/NCT03625323
NCT02323126	EGF816	Phase 2	Recruiting	23/12/2014	09/02/2015	A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer	Capmatinib; Capmatinib + Nivolumab; Nazartinib; Nazartinib + Nivolumab; Nivolumab	EGFR_inhibitor,third_generation + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1; EGFR_inhibitor,third_generation; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	2014-003731-20; CEGF816X2201C	A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer	Non Small Cell Lung Cancer	Novartis Investigative Site - Camperdown; Novartis Investigative Site - Chermside; Novartis Investigative Site - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02323126
NCT03539536	M14-239	Phase 2	Recruiting	29/05/2018	10/10/2018	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met positive Non-Small Cell Lung Cancer	Telisotuzumab Vedotin	anti-c-Met_antibody-drug_conjugate	2018-001772-38; M14-239	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	The Kinghorn Cancer Centre /ID# 207666 - Darlinghurst; Newcastle Private Hospital /ID# 206600 - Lambton Heights; The Tweed Hospital /ID# 206601 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT03539536
ACTRN12614001248651	MesomiR-1	Phase 1	Recruiting	28/11/2014	29/09/2014	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Dexamethasone; TargomiRs	glucocorticoid; miR-16_miRNA_mimic	Nil	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Malignant Pleural Mesothelioma; Advanced Non Small Cell Lung Cancer	Concord Repatriation Hospital - Concord; The Chris O’Brien Lifehouse - Camperdown; Northern Cancer Institute - Frenchs Forest - Frenchs Forest	https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366143
NCT03974022	DZ2019E0001	Phase 1/Phase 2	Recruiting	04/06/2019	09/07/2019	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	DZD9008	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	DZ2019E0001	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	NonSmall Cell Lung Cancer	Linear Cancer trials - Perth	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT04194944	LIBRETTO-431	Phase 3	Recruiting	11/12/2019	16/03/2020	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Selpercatinib	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; antimetabolite; RET_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	J2G-MC-JZJC; 17479	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Chris O'Brien Lifehouse - Camperdown; Calvary Mater Newcastle - Newcastle; Westmead Hospital - Wentworthville; Princess Alexandra Hospital - Woolloongabba; Monash Medical Centre - Clayton; St Vincents Hospital Melbourne - Fitzroy; Peter MacCallum Cancer Centre - Melbourne; Peninsula &amp; South Eastern Haematology and Oncology Group - Frankston	https://clinicaltrials.gov/ct2/show/NCT04194944
NCT03497767	OUTRUN	Phase 2	Recruiting	13/04/2018	15/08/2019	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Osimertinib	EGFR_inhibitor,third_generation	TROG 17.02	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	Calvary Mater - Newcastle; Liverpool Hospital - Sydney; St. Vincents Hospital - Sydney; Chris O'Brien Lifehouse - Sydney; Westmead Hospital - Sydney; Blacktown Hospital - Sydney; St George Hospital - Sydney; Princess Alexandra Hospital - Brisbane; ICON Cancer Centre Greenslopes - Brisbane; Peter MacCallum Cancer Center - Melbourne; Monash Health - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03497767
ACTRN12618001121257	POPCORN	Phase 1 / Phase 2	Recruiting	06/07/2018	22/05/2019	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Denosumab; Nivolumab	anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody	20177440 Amgen ISS	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	Royal Brisbane &amp; Womens Hospital - Herston; The Prince Charles Hospital - Chermside; Princess Alexandra Hospital - Woolloongabba	https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375442
NCT04051827	TAK-788-1004	Phase 1	Recruiting	09/08/2019	23/12/2019	A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer	Midazolam; Midazolam + TAK-788; TAK-788	EGFR_inhibitor,exon_20_selective + benzodiazepam; EGFR_inhibitor,exon_20_selective; benzodiazepam	2019-000725-44; TAK-788-1004	A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms	Royal North Shore Hospital - St Leonards; Flinders Medical Centre - Bedford Park; Peninsula and Southeast Oncology - Frankston; Nucleus Network - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04051827
NCT03626545	CANOPY-2	Phase 3	Recruiting	13/08/2018	08/01/2019	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)	Cisplatin; Docetaxel; Docetaxel + canakinumab; Placebo; canakinumab	taxane; anti-IL-1beta_antibody; placebo; anti-IL-1beta_antibody + taxane; platinum-based_antineoplastic_agent	2018-002480-26; CACZ885V2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)	Non-Small-Cell Lung	Novartis Investigative Site - Greenslopes; Novartis Investigative Site - Shepparton	https://clinicaltrials.gov/ct2/show/NCT03626545
ACTRN12619000844145	ALKternate	Phase 1 / Phase 2	Recruiting	13/06/2019	14/06/2019	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	Crizotinib; Lorlatinib	MET_inhibitor,type_1; ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation	None	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	Royal North Shore Hospital - St Leonards; Peter MacCallum Cancer Centre - Melbourne	https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377668
NCT03088813	RESILIENT	Phase 2/Phase 3	Recruiting	23/03/2017	25/04/2018	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy	Cisplatin; Irinotecan; Topotecan	platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2017-004261-26; MM-398-01-03-04	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy	Small Cell Lung Cancer	Border Medical Oncology Research Unit - Albury; Peninsula &amp; South Eastern Haematology and Oncology Group - Frankston; South West Healthcare - Warrnambool; Southern Medical Day Care Centre - Wollongong; Princess Alexandra Hospital - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03088813
NCT04035486	FLAURA2	Phase 3	Recruiting	29/07/2019	02/07/2019	A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced Non-Small Cell Lung Cancer (FLAURA2)	Carboplatin; Carboplatin + Cisplatin + Osimertinib + Pemetrexed; Cisplatin; Osimertinib; Pemetrexed	EGFR_inhibitor,third_generation + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; antimetabolite; platinum-based_antineoplastic_agent	D5169C00001	A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced Non-Small Cell Lung Cancer (FLAURA2)	Non-Small Cell Lung Cancer	Research Site - Chermside; Research Site - Heidelberg; Research Site - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04035486
NCT04154956	CARMEN-LC03	Phase 3	Recruiting	07/11/2019	06/02/2020	Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors	Docetaxel; SAR408701	anti-CEACAM5_antibody-drug_conjugate; taxane	2019-001273-81; EFC15858	Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors	Non-small Cell Lung Cancer Metastatic	Investigational Site Number 0360002 - Blacktown; Investigational Site Number 0360003 - Waratah; Investigational Site Number 0360001 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04154956
NCT03743064	ANAM-17-21	Phase 3	Recruiting	15/11/2018	18/12/2018	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Anamorelin; Placebo	Growth_hormone_secretagogue_receptor_agonist; placebo	2018-002927-40; ANAM-17-21	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Cachexia; Cancer; Non Small Cell Lung Cancer	Flinders Medical Centre - Bedford Park; St Vincent's Hospital Melbourne - Fitzroy; Barwon Health, The McKellar Centre - North Geelong; The Royal Melbourne Hospital - Parkville; Gold Coast University Hospital - Southport	https://clinicaltrials.gov/ct2/show/NCT03743064
NCT03215706	CheckMate-9LA	Phase 3	Recruiting	12/07/2017	20/07/2017	A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	Carboplatin; Cisplatin; Ipilimumab; Nivolumab; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; taxane	2017-001195-35; CA209-9LA	A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Local Institution - Gosford; Local Institution - Bedford Park; Local Institution - Elizabeth Vale; Local Institution - Box Hill; Local Institution - Heidelberg; St John of God Murdoch Hospital - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03215706
NCT02477826	CheckMate-227	Phase 3	Recruiting	23/06/2015	05/08/2015	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Carboplatin; Cisplatin; Cisplatin + Nivolumab; Gemcitabine; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; taxane; antimetabolite; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody	2014-003630-23; CA209-227	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	Local Institution - Garran; Blacktown Hospital - Blacktown; Local Institution - Gosford; Tamworth Hospital - Tamworth; Princess Alexandra Hospital - Brisbane; Local Institution - Elizabeth Vale; Local Institution - Clayton; St Vincent's Hospital - Fitzroy; Local Institution - Perth; Local Institution - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02477826
NCT03906331	Selpercatinib-EAP		Available	08/04/2019		Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Selpercatinib	RET_inhibitor	Selpercatinib EAP; Selpercatinib EAP	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	Chris O'Brien Lifehouse - Camperdown; The Prince Charles Hospital - Chermside; Peter MacCallum Cancer Centre - Melbourne; Linear Clinical Research - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT02735980	I4D-MC-JTJH	Phase 2	Recruiting	07/04/2016	01/05/2016	A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer	Cisplatin; Cisplatin + Prexasertib; Prexasertib	platinum-based_antineoplastic_agent; CHEK1_inhibitor; CHEK1_inhibitor + platinum-based_antineoplastic_agent	I4D-MC-JTJH; 16015	A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer	Small Cell Lung Cancer	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Bedford Park; For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Concord; For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Herston; For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Melbourne; For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Randwick; For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - South Brisbane; For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wentworthville	https://clinicaltrials.gov/ct2/show/NCT02735980
NCT02408861	AMC-095	Phase 1	Recruiting	03/04/2015		A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461; PAMC-095_R03PAPP01; AMC-095; AMC-095; AMC-095; U01CA121947; UM1CA121947	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Advanced Malignant Solid Neoplasm; Anal Carcinoma; HIV Infection; Kaposi Sarcoma; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma; Unresectable Solid Neoplasm	Saint Vincent's Hospital; University of New South Wales	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT03138889	PROPEL	Phase 1/Phase 2	Recruiting	01/05/2017		A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Bempegaldesleukin; Bempegaldesleukin + Pembrolizumab; Pembrolizumab	IL-2_variant; anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody		A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Non-Small Cell Lung Cancer; Melanoma; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma	Investigator Site - Richmond	https://clinicaltrials.gov/ct2/show/NCT03138889
NCT03175224	SPARTA	Phase 1/Phase 2	Recruiting	01/06/2017		Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Bozitinib	MET_inhibitor		Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Solid Tumor; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; NSCLC; Lung Cancer; Brain Tumor; Glioblastoma Multiforme	Calvary Central Districts Hospita; Flinders Medical Centre; Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03468426	2017-001378-41	Phase 1	Recruiting	15/03/2018		An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With BI 754091 to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors	BI 754091	anti-PD-1_monoclonal_antibody	2017-001378-41	An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With BI 754091 to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors	Non-squamous, Non-Small-Cell Lung Cancer; Neoplasms	Alfred Hospital; Chris Obrien Lifehouse; Peninsula &amp; South Eastern Oncology Group; Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03468426
NCT03639714	NCT03639714	Phase 1/Phase 2	Recruiting	18/08/2018		An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors	Ipilimumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody		An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors	Non Small Cell Lung Cancer; Colorectal Cancer; Gastroesophageal Adenocarcinoma; Urothelial Carcinoma	Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03639714
NCT03840902	2018-003265-34	Phase 2	Recruiting	12/02/2019		A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer	Bintrafusp Alfa; Bintrafusp Alfa + Carboplatin + Cisplatin + Durvalumab + Etoposide + Paclitaxel + Pemetrexed; Bintrafusp Alfa + Carboplatin + Cisplatin + Etoposide + Paclitaxel + Pemetrexed; Carboplatin; Cisplatin; Durvalumab; Etoposide; Paclitaxel; Pemetrexed; Placebo	anti-PD-L1_monoclonal_antibody; taxane; placebo; antimetabolite; anti-PD-L1_and_TGF-beta_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent + taxane + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-L1_and_TGF-beta_monoclonal_antibody; anti-PD-L1_and_TGF-beta_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent + taxane + topoisomerase_inhibitor; platinum-based_antineoplastic_agent	2018-003265-34	A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	Austin Health; Bendigo Hospital; Calvary Central Districts Hospital; Centro de Investigacion Pergamino SA; Prince of Wales Hospital; South West Healthcare - South West Oncology; St Vincent's Hospital Melbourne - PARENT; Sunshine Hospital; The Townsville Hospital	https://clinicaltrials.gov/ct2/show/NCT03840902
NCT04032704	NCT04032704	Phase 2	Recruiting	23/07/2019		Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Ladiratuzumab Vedotin	anti-LIV-1_antibody-drug_conjugate		Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Non-small Cell Lung Cancer, Non-squamous; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma	Cabrini; Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04032704
NCT04129502	NL20191212	Phase 3	Recruiting	15/10/2019		A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Pemetrexed; TAK-788	platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent + platinum-based_antineoplastic_agent; antimetabolite	NL20191212; 2019-001845-42; U1111-1232-6059	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Flinders Medical Centre; Northern Cancer Institute, St Leonards; Princess Alexandra Hospital; Royal Hobart Hospital; St George Hospital	https://clinicaltrials.gov/ct2/show/NCT04129502
NCT04248829	NCT04248829	Phase 3	Recruiting	28/01/2020		A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Gefitinib; Gefitinib + Lazertinib; Lazertinib; Placebo	EGFR_inhibitor,first_generation; EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; placebo		A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Peninsula &amp; South Eastern Haematology and Oncology Group; Princess Alexandra Hospital; The Townsville Hospital	https://clinicaltrials.gov/ct2/show/NCT04248829
NCT04262856	ARC-7	Phase 2	Recruiting	07/02/2020		A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	AB122; AB154; AB154 + AB928; AB928	anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist		A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer	Adelaide Cancer Centre; Border Medical Oncology; Coffs Harbour Health Campus; Shoalhaven Cancer Care Centre; Tweed Hospital	https://clinicaltrials.gov/ct2/show/NCT04262856
NCT04282018	NCT04282018	Phase 1/Phase 2	Recruiting	20/02/2020		A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Tislelizumab; Zanubrutinib	BTK_inhibitor; anti-PD-1_monoclonal_antibody		A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Advanced Solid Tumor; Non-small Cell Lung Cancer; Metastatic Melanoma	Austin Hospital - Hematology; Monash Hospital - Hematology; Perth Blood Institute; St. Vincent Hospital - Sydney - Hematology/Oncology	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04297748	NCT04297748	Phase 1/Phase 2	Recruiting	04/03/2020		A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy	Bintrafusp Alfa; Bintrafusp Alfa + Carboplatin + Pemetrexed; Carboplatin; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; anti-PD-L1_and_TGF-beta_monoclonal_antibody; anti-PD-L1_and_TGF-beta_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent		A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy	Non-Small Cell Lung Cancer	Austin Health	https://clinicaltrials.gov/ct2/show/NCT04297748
NCT04300244	NIPU	Phase 2	Recruiting	05/03/2020		Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Sargramostim	Granulocyte-Macrophage_Colony_Stimulating_Factor; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody		Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Cancer; Cancer, Lung; Cancer of Lung; Mesothelioma; Mesothelioma; Lung; Mesothelioma; Pleura; Mesotheliomas Pleural	University of Western Australia	https://clinicaltrials.gov/ct2/show/NCT04300244
NCT04430842	NCT04430842	Phase 1	Recruiting	10/06/2020		A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma				A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma	Astrocytoma; Brain Cancer; Brain Metastases; Bladder Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Pleural Mesothelioma; Prostate Cancer; Sarcoma; Tongue Cancer; Thymic Carcinoma; Urinary Tract Cancer	St George Private Hospital; Sydney Southwest Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04430842
NCT04432207	NCT04432207	Phase 1	Recruiting	11/06/2020		An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	IMU-201	B_cell_immunotherapy		An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Squamous Non-small-cell Lung Cancer; Large Cell Carcinoma Lung; Adenocarcinoma Lung	Cabrini Malvern Hospital; Chris O'Brien Lifehouse; Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04432207
NCT04449874	2020-000084-22	Phase 1	Recruiting	24/06/2020		A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	GDC-6036	KRAS_G12C_inhibitor	2020-000084-22	A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors	Peter MacCallum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04471428	CONTACT-01	Phase 3	Recruiting	10/07/2020		A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Cisplatin; Docetaxel	platinum-based_antineoplastic_agent; AXL_inhibitor; ROS1_inhibitor; RET_inhibitor; MET_inhibitor,type_2; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody		A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Affinity Oncology; Austin Hospital Olivia Newton John Cancer Centre; Flinders Medical Centre; Royal North Shore Hospital; Oncology; Townsville Hospital	https://clinicaltrials.gov/ct2/show/NCT04471428
NCT04513925	SKYSCRAPER-03	Phase 3	Recruiting	13/08/2020		A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation	Atezolizumab; Atezolizumab + Tiragolumab; Cisplatin; Durvalumab; Tiragolumab	anti-TIGIT_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-004773-29	A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation	Non-small Cell Lung Cancer (NSCLC)	Blacktown Hospital; Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit; Flinders Medical Centre; Macarthur Cancer Therapy Centre; Monash Health Translational Precinct; Clinical Trials Centre, Level 3; Princess Alexandra Hospital; St George Hospital; Cancer Care Centre	https://clinicaltrials.gov/ct2/show/NCT04513925
